{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:12:38Z","timestamp":1791839558843,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.medcli.2024.05.007","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T04:21:14Z","timestamp":1720930874000},"page":"391-396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Reacciones adversas a inhibidores de quinasa Janus: estudio de su incidencia y de factores predictivos en los pacientes con artritis reumatoide"],"prefix":"10.1016","volume":"163","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5079-613X","authenticated-orcid":false,"given":"Cristina","family":"Martinez-Molina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5537-2600","authenticated-orcid":false,"given":"Jose Maria","family":"Guardiola Tey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0008-641X","authenticated-orcid":false,"given":"Jesus","family":"Ruiz-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2074-2231","authenticated-orcid":false,"given":"Anna","family":"Feliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6416-3341","authenticated-orcid":false,"given":"Mireia","family":"Puig-Campmany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3909-6682","authenticated-orcid":false,"given":"Silvia","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7738-6787","authenticated-orcid":false,"given":"H\u00e8ctor","family":"Corominas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2024.05.007_bib0155","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1592\/phco.22.11.915.33630","article-title":"Drug-related visits to the emergency department: How big is the problem?","volume":"22","author":"Patel","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.medcli.2024.05.007_bib0160","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/ijpp\/riad022","article-title":"Drug-related problems as reason for emergency department visit: 3 years of the FARM-URG registry","volume":"31","author":"Ruiz-Ramos","year":"2023","journal-title":"Int J Pharm Pract"},{"key":"10.1016\/j.medcli.2024.05.007_bib0165","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00228-006-0116-0","article-title":"Medicine-related problems resulting in emergency department visits","volume":"62","author":"Baena","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.medcli.2024.05.007_bib0170","first-page":"415","article-title":"EVADUR: eventos adversos ligados a la asistencia en los servicios de urgencias de hospitales espa\u00f1oles","volume":"22","author":"Tom\u00e1s Vecina","year":"2010","journal-title":"Emergencias"},{"key":"10.1016\/j.medcli.2024.05.007_bib0175","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: A review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2024.05.007_bib0180","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2024.05.007_bib0185","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2024.05.007_bib0190","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.medcli.2024.05.007_bib0195","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2024.05.007_bib0200","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medcli.2024.05.007_bib0205","doi-asserted-by":"crossref","first-page":"ii24","DOI":"10.1093\/rheumatology\/keaa895","article-title":"The safety of JAK-1 inhibitors","volume":"60","author":"Clarke","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.medcli.2024.05.007_bib0210","article-title":"Selectivity, efficacy and safety of JAKinibs: New evidence for a still evolving story","author":"Bonelli","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2024.05.007_bib0215","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2024.05.007_bib0220","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.medcli.2024.05.007_bib0225","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.medcli.2024.05.007_bib0230","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","article-title":"Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis","volume":"58","author":"Harigai","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.medcli.2024.05.007_bib0235","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/1744666X.2022.2014323","article-title":"The infection risks of JAK inhibition","volume":"18","author":"Adas","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.medcli.2024.05.007_bib0240","doi-asserted-by":"crossref","first-page":"1241954","DOI":"10.3389\/fphar.2023.1241954","article-title":"Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: A systematic review and network meta-analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.medcli.2024.05.007_bib0245","article-title":"Medicines and Healthcare products Regulatory Agency (UK). Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors","year":"2020","journal-title":"Drug Safety Update"},{"key":"10.1016\/j.medcli.2024.05.007_bib0250","doi-asserted-by":"crossref","first-page":"204","DOI":"10.7150\/ijbs.51362","article-title":"Biological characteristics of IL-6 and related intestinal diseases","volume":"17","author":"Guo","year":"2021","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.medcli.2024.05.007_bib0255","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical significance of Janus Kinase inhibitor selectivity","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.medcli.2024.05.007_bib0260","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis.V 80"},{"key":"10.1016\/j.medcli.2024.05.007_bib0265","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41598-023-50379-8","article-title":"Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study","volume":"14","author":"Martinez-Molina","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.medcli.2024.05.007_bib0270","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/ard-2022-223715","article-title":"Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: An analysis of the open label, randomised controlled study ORAL Surveillance","volume":"82","author":"Kristensen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2024.05.007_bib0275","article-title":"European Medicines Agency (EMA). EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders","year":"2023","journal-title":"EMA"},{"key":"10.1016\/j.medcli.2024.05.007_bib0280","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/ard-2022-222835","volume":"82","author":"Pombo-Suarez","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2024.05.007_bib0285","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/art.38779","article-title":"Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis","volume":"66","author":"Cohen","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.medcli.2024.05.007_bib0290","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/annrheumdis-2021-221957","article-title":"Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: The pragmatic randomised, double-blind placebo-controlled GLORIA trial","volume":"81","author":"Boers","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2024.05.007_bib0295","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41598-021-04075-0","article-title":"Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: The ANSWER cohort study","volume":"12","author":"Ebina","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.medcli.2024.05.007_bib0300","doi-asserted-by":"crossref","first-page":"e000742","DOI":"10.1136\/rmdopen-2018-000742","article-title":"Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib","volume":"5","author":"Bird","year":"2019","journal-title":"RMD Open"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775324003816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775324003816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T06:28:40Z","timestamp":1729319320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775324003816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0025775324003816"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2024.05.007","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reacciones adversas a inhibidores de quinasa Janus: estudio de su incidencia y de factores predictivos en los pacientes con artritis reumatoide","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2024.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}